Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vibrant IVDs Innovation Climate At Risk From Poor UK Regulatory System Readiness

Executive Summary

The spotlight is on IVDs in the post-COVID phase. Innovators in university spin-outs and the established industry have responded with new technologies, creating a vibrant scene. Regulators and reimbursors must not disrupt the momentum, say BIVDA’s regulatory affairs manager Ashleigh Batchen and chief executive Doris-Ann Williams.

You may also be interested in...



DEKRA Accredited To Audit Against UKCA Marking, But More UK Capacity Needed

A fourth approved body has been accredited to audit medical device submissions against the UKCA marking. A fifth is thought to be not far behind, but current assumptions are that overall auditing capacity will not be adequate under the forthcoming UK medical device regulations.

Industry's Verdict On UK Medtech Regulatory System Progress: 'Could Do Better’

The UK’s new medical device regulations remain a work in progress, ahead of the parliamentary process and codification into law in 2023. The ABHI’s Phil Brown says industry will continue to advise the government on how to maximize fully the rare opportunity the UK stands before.

MHRA Offers Medtechs Extra Transition Time For UK Regulatory System Compliance

26 June saw the release finally of the UK government’s official response to the MHRA’s 2021 consultation on its post-Brexit medical devices regulatory framework. The considered response, held up by political and internal timing issues, represents an implementation plan for reform of the system. Crucially it allows industry extra compliance time.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT145715

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel